Human biomonitoring in Europe: the Vienna stakeholder conference

This page preserves the welcome and background material for the Vienna stakeholder conference. Its focus is the event itself: the meeting setting, the three thematic sessions and the connection between human biomonitoring research and policy discussion. For a navigable timetable with named contributors, use the programme and speaker list.

The original conference took place in 2018. Statements about planned attendance and historical contact arrangements below should therefore be read as archived information, not current announcements. Readers seeking the broader project context can use the separate HBM4EU initiative overview.

deutsche version | english version

Under the Austrian EU presidency an international conference entitled
“Human biomonitoring in Europe – science and policy for healthy citizens”

took place in Vienna, Austria on 28 September 2018

This high-level Stakeholder Conference under the auspices of the Austrian Presidency and the European Commission highlighted the benefits of human biomonitoring for policy making, presented the first results of the European HBM4EU joint initiative and contributed to shaping the future of Human Biomonitoring in Europe.

Human biomonitoring is about detecting (traces of) chemicals in our bodies to improve public health. Since chemicals are widely used in food and consumer products, and the exposure to chemicals concerns all citizens, this conference will be attended by high-level representatives from all EU Member States as well as representatives of the European Commission and other key stakeholders.

Conference Video

Programme

After the opening of the conference and the welcome by the Austrian presidency and the European Commission an introduction to the European Human Biomonitoring Initiative HBM4EU was given.

The Conference included 3 sessions covering different aspects of Human Biomonitoring in Europe.

Session A presented highlights of how Human Biomonitoring contributes to policy making. In session B results of HBM4EU were presented and new challenges in HBM and risk assessment were addressed. Session C brought perspectives and views on the future of Human Biomonitoring in Europe.

Programme and Presentations